Skip to content

Johns Hopkins Crohn's Disease and Ulcerative Colitis Study

Johns Hopkins Crohn's Disease and Ulcerative Colitis Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01169207
Enrollment
2500
Registered
2010-07-26
Start date
1996-07-01
Completion date
2027-12-01
Last updated
2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Keywords

Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, IBD, CD, UC, IC

Brief summary

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a idiopathic, chronic and frequently disabling inflammatory disorder of the intestines characterized by a dysregulated mucosal immune response that affect more than a million Americans. This current protocol was established in 1996 with the goal of identifying the genetic and environmental components that contribute to the development of IBD, especially in families.

Detailed description

The investigators initiated this research study in 1996 with the overall goal of identifying IBD susceptibility genes. In the beginning, the major focus was recruitment of multiply affected IBD pedigrees for linkage studies, but the investigators have since expanded the study to include singleton cases and spousal/friend as well as population controls for comparison purposes The investigator's recruitment goal is 2500 subjects. Blood samples obtained from participants are used to isolate lymphocytes for storage, serum for serological analysis of antibodies and other proteins relevant to IBD and DNA for genotyping or sequencing. Lymphocytes may be transformed with EBV to establish immortalized lymphoblastoid cell lines. These cell lines can be used as a secondary DNA source or to study IBD relevant gene, protein expression and cell function

Interventions

None listed

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

ADULTS: * Patients with IBD and family members who have or do not have IBD. * People that do not have IBD nor have a family member with IBD needed for comparison purposes. CHILDREN: * Children age 5 or older with IBD and family members who have or do not have IBD. * Children that do not have IBD nor have a family member with IBD needed for comparison purposes.

Exclusion criteria

* The only exclusions are age parameters and health reasons that would preclude enrollment; such as, for anemic patients. Blood-draws on anemic patients may, in certain medical cases, pose a health risk; therefore, the investigators request that if the participants are anemic that the participants present a letter from the participant's personal physician giving explicit permission for the participant to join if at the time it is clinically advisable.

Design outcomes

Primary

MeasureTime frame
Genetics of IBDSingle visit, approximately 1 hour

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORFlorin Selaru, M.D.

Johns Hopkins University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026